RT Journal Article
T1 Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
A1 Sánchez-Muñoz, Alfonso
A1 Mendiola, César
A1 Pérez-Ruiz, Elisabeth
A1 Rodríguez-Sánchez, César A.
A1 Jurado, José Miguel
A1 Alonso-Carrión, Lorenzo Javier
A1 Ghanem, Ismael
A1 Velasco, Guillermo de
A1 Quero-Blanco, Cristina
A1 Alba-Conejo, Emilio
K1 Ovarios - Cáncer - Tratamiento
AB Aim: To retrospectively assess the efficacy and safety of bevacizumab plus low-dose metronomic oral cyclophosphamidein heavily pretreated patients with recurrent ovarian cancer. Patients and Methods: Patients with recurrent ovariancancer and prior treatment with platinum- and taxanebased chemotherapy were included. Treatment consisted ofbevacizumab 10 mg/kg intravenously every 2 weeks plus oral cyclophosphamide 50 mg daily until disease progressionor unacceptable toxicity. Response rates (RR) were determined according to RECIST criteria and by monitoring theCA 125 serum tumor marker according to Rustin’s criteria.The endpoints were progression-free survival (PFS), RR, overallsurvival (OS), and safety. Results: Thirty-eight patients were treated; 79% were platinum resistant and 21% wereplatinum sensitive. The median number of previous treatments was 4 (range 1–8). Seventy-nine percent of patientshad received more than 2 previous lines of treatment. Eightyone percent of patients had received gemcitabine, 76% liposomaldoxorubicin, and 50% topotecan. A median of 8 (range 1–70) cycles of bevacizumab were administered. The overallRR was a complete response (CR) in 3 patients (8.1%), a partial response (PR) in 12 (32.4%), and stable disease (SD) 6 6months in 3 (8.1%). The median PFS and OS were 4.5 and 10.7 months, respectively. Thirty-nine percent of patients wereprogression free for at least 6 months. In an exploratory analysis there was a significant relation of prior platinum responseand performance status with the risk of progression.Grade 3–4 toxicities included anemia (1), hypertension (2),hematuria (1), arterial thrombosis in the leg (1), dyspnea (1), and intestinal fistulae (1). There were no cases of gastrointestinalperforation (GIP) or treatment-related deaths. Conclusion: The combination of bevacizumab and metronomic cyclophosphamidewas active and well-tolerated in heavily pretreated patients with recurrent ovarian cancer.
PB KARGER
YR 2010
FD 2010-11
LK https://hdl.handle.net/10630/30049
UL https://hdl.handle.net/10630/30049
LA eng
NO Sánchez-Muñoz A, Mendiola C, Pérez-Ruiz E, Rodríguez-Sánchez CA, Jurado JM, Alonso-Carrión L, Ghanem I, de Velasco G, Quero-Blanco C, Alba E. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Oncology. 2010;79(1-2):98-104. doi: 10.1159/000320602. Epub 2010 Nov 15. PMID: 21079407.
NO Este artículo ha sido publicado en Oncology Basel.Esta versión tiene Licencia Creative Commons CC-BY-NC-NDNo puedo enviar el postprint porque no lo tienen disponible o no quieren facilitarmelo, en su lugar he aportado en la descripción del envió dos e mail en los cuales la editorial me da permiso por escrito para su depósito como puede ver en los mimosAdjunto  e mails, si tiene ustd alguna otra sugerencia  para poder hacer deposito por favor hagamelo saber2º e mail:Dear Alfonso,Our reply is the written permission to deposit the article in the university’s repository – please find it attached once again.Kind regards,Veronika1º e mailVeronika DuhovnikovaKey Account Manager, Academic & Research Markets+41 61 306 12 43v.duhovnikova@karger.comDear Alfonso,Thank you for your email. As to your query, we are pleased to inform you that Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following the publication of the publisher’s versions.For all self-archiving options, the posted manuscripts must be - used for non-commercial purposes only- linked to the final version on Karger Publishers- include the following statement: ‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Oncology 1 December 2010; 79 (1-2): 98–104, (DOI: 10.1159/000320602)]. The final, published version is available at [https://karger.com/ocl/article-abstract/79/1-2/98/328844/Bevacizumab-plus-Low-Dose-Metronomic-Oral?redirectedFrom=fulltext].’For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.It is the author’s responsibility to fulfil these requirements. Further information about Karger’s Self-Archiving Policy can be found on the Karger website https://karger.com/pages/rights-and-permissions ‘How can I share it?’ and on SherpaRomeo Welcome to Sherpa Romeo - v2.sherpa.Please feel free to contact us again, if you need any further information. Kind regards,VeronikaVeronika DuhovnikovaKey Account Manager, Academic & Research Markets+41 61 306 12 43v.duhovnikova@karger.com
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 3 mar 2026